Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

Quick answer

Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate for This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C. is a Phase 1 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).